Brainstorm Cell Therapeutics (NASDAQ:BCLI) coverage initiated by analysts at StockNews.com

StockNews.com has begun coverage of the stock Brainstorm Cell Therapeutics (NASDAQ:BCLI – Free Report) in a research note published on Thursday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, Maxim Group raised Brainstorm Cell Therapeutics from a hold rating to a buy rating and set a $2.00 price target for the company in a research note on Thursday, July 11th.

Check out our latest research report on BCLI

Brainstorm Cell Therapeutics Stock Performance

BCLI stock opened at $0.34 on Thursday. The company’s 50-day moving average price is $0.36, and its two-hundred-day moving average price is $0.43. Brainstorm Cell Therapeutics has a 52-week low of $0.13 and a 52-week high of $1.81. The stock has a market cap of $23.97 million, a PE ratio of -1.08 and a beta of 0.37.

Brainstorm Cell Therapeutics (NASDAQ:BCLI – Get Free Report ) last posted its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04). During the same period in the previous year, the company earned ($0.27) earnings per share. As a group, sell-side analysts forecast that Brainstorm Cell Therapeutics will post -0.14 earnings per share for the current fiscal year.

Institutional Trading of Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Kingswood Wealth Advisors LLC purchased a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI – Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 81,050 shares of the biotechnology company’s stock, valued at approximately $46,000. Kingswood Wealth Advisors LLC owned approximately 0.12% of Brainstorm Cell Therapeutics at the end of the most recent reporting period. 14.33% of the shares are currently held by hedge funds and other institutional investors.

About Brainstorm Cell Therapeutics

(Get a free report)

Brainstorm Cell Therapeutics Inc, a biotechnology company, is engaged in the development and commercialization of autologous cell therapies for the treatment of neurodegenerative diseases. The company, through its proprietary cell therapy platform NurOwn, uses cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and to improve neurological function.

See Also

Get Brainstorm Cell Therapeutics news and reviews daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.